Lymphoma, Non-Hodgkin Clinical Trial
Official title:
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Verified date | March 2015 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to learn the effects of an investigational medication, SGN 35, on patients with mycosis fungoides. Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.
Status | Active, not recruiting |
Enrollment | 36 |
Est. completion date | October 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient has biopsy-proven MF/SS, stage IB-IVB, and failed one standard systemic therapy. - Skin biopsy will be obtained within 3 months of beginning study medication, for assessment of CD30 expression by immunohistochemistry (IHC). This data will be used to ensure equal enrollment of patients in the 3 groups of varying CD30 expression (low, intermediate, high). If patient has different lesion morphology (patch, plaque, tumor), a biopsy will be obtained from each morphologic lesion. If the patient has one type of lesion morphology, a biopsy from 2 separate anatomic sites will be obtained. - The highest CD30 expression value among biopsies will be used to determine which of the 3 groups the subject will be assigned to. 2. Patients must have the following minimum wash-out from previous treatments: - >= 3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-cancer investigational agents (including monoclonal antibody). - > 3 weeks for retinoids, interferons, vorinostat, romidepsin, denileukin diftitox. - > 3 wks for phototherapy. - > 2 wks for topical therapy (including topical steroid, retinoid, nitrogen mustard, or imiquimod). 3. At least 18 years of age. 4. ECOG performance status of <= 2. 5. Patients must be available for study treatment, blood sampling, study assessments, and management of toxicity at the treating institution. 6. Adequate baseline laboratory data: absolute neutrophil count (ANC) >= 1000/uL, platelets >= 50,000/uL, bilirubin <= 2X upper limit of normal (ULN) or <= 3X ULN for patients with Gilbert's disease, serum creatinine <= 2X ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3X ULN. 7. Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days of treatment. 8. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patients with mycosis fungoides (MF) with limited disease (stage IA) or central nervous system (CNS) disease. 2. Concomitant corticosteroid use, systemic or topical, for treatment of skin disease. Oral prednisone is allowed at <= 10 mg/day, if patient has been on a stable dose for at least 1 month prior to study entry. 3. Patients with known Grade 3 or higher (per NCI CTCAE v4.0 criteria) active systemic or cutaneous viral, bacterial, or fungal infection. 4. Patients who are known to be Hepatitis B or Hepatitis C antibody positive. 5. Patients who are HIV-positive, and have a measurable viral load while on antiretrovirals. 6. Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation. 7. Patients with a history of other malignancies during the past three years. (The following are exempt from the three-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, curatively treated localized breast cancer, resected thyroid cancer, cervical intraepithelial neoplasia or cervical carcinoma in situ on biopsy). 8. Patients who are currently pregnant or breastfeeding. 9. Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria. 10. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment. 11. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Youn Kim | Seattle Genetics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective clinical response rate assessed by the standard response criteria used in MF (Mycosis fungoides) and SS (Sezary syndrome) | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03484702 -
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Completed |
NCT06190457 -
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
|
||
Completed |
NCT02369016 -
Phase III Copanlisib in Rituximab-refractory iNHL
|
Phase 3 | |
Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
Terminated |
NCT00529503 -
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
|
Phase 2 | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Withdrawn |
NCT00319332 -
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
|
Phase 3 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Completed |
NCT00322842 -
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
|
Phase 2 | |
Completed |
NCT00141297 -
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02509039 -
A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
|
Phase 1 | |
Completed |
NCT00268203 -
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT01573000 -
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
|
Phase 2 | |
Completed |
NCT03289182 -
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
|